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Abstract 
Health technology assessment (HTA) has, in the past three decades, become a well-established part of 
coverage decisions in many countries. Despite this, very little is known about HTA’s impact on health 
systems. Few studies evaluate the benefits of HTA for health outcomes, access to care or public budgets. 
In contrast, HTA has relatively clear upfront costs, which could potentially discourage policy-makers 
from institutionalizing HTA, especially in resource-tight contexts. It may be premature, though, to 
dismiss the policy altogether: its less tangible modernizing goals are still significant.  
 
Introduction 
Health technology assessment (HTA) has been one of the most popular policy tools of health care 
reimbursement, pricing and purchasing of the past thirty years. With the aim of informing coverage 
decisions by means of multidisciplinary evaluation of evidence, HTA has the backing of a large epistemic 
community. Public and private consultancies spread the message of HTA around the world (1,2), as do 
international actors such as the World Health Organization (3), the World Bank (4) and the European 
Union (5), and international professional networks such as HTAi, ISPOR, RedETSA, HTAsiaLink and 
EUnetHTA (6).  
Indeed, many governments have been seduced by HTA’s promise: to improve allocation of resources in 
health care. Since the late 1980s, most of Western Europe as well as Australia, New Zealand, Canada and 
several US payer organizations have established dedicated HTA agencies. Some Asian (e.g. Taiwan), 
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Latin American (e.g. Brazil) and Central and Eastern European (e.g. Poland) countries followed in the 
early 2000s. Other countries, however, have been more hesitant to institutionalize HTA bodies. This piece 
explores what health technology assessment has to offer to decision-makers of countries without 
institutionalized HTA, especially in low and middle resource contexts.  
 
Vague benefits 
Health economists agree that HTA is especially important in resource-tight contexts because opportunity 
costs of misdirected resources are higher, in relative terms, than in rich economies (7,8). This is a 
convincing claim. However, empirical evidence of the impact of HTA on either health outcomes or 
spending, the end goals of HTA, is scarce.  
Policy evaluation of HTA is practically non-existent (9–11). A 2008 review found that only four 
published studies assessed the impact of HTA on health outcomes or spending (12). Most studies focus on 
outputs of HTA agencies (e.g. number of HTA reports produced) and the extent to which conclusions of 
HTA reports are followed by decision-makers (10)  – leading an observer to conclude that “the available 
knowledge to assess the effectiveness of HTA is just a bunch of ‘case series’ and ‘case reports’, with little 
external validity and usually surrogate outcomes” (13). Indeed, we know next to nothing about HTA’s 
impact on health outcomes (9). An Austrian study, one of the most comprehensive country-level 
evaluations to date, excludes health outcomes “due to methodological limitations” (14). Similarly, a 
recent report on the United Kingdom’s HTA program found that HTA has had an impact on patients’ 
care, but it did not assess outcomes (15). Improved access to care as a result of institutionalized HTA is 
not explicitly mentioned in any reviews (9), except for an industry-commissioned report (16). Finally, 
evaluations of economic impact are mixed. An early Canadian study found projected annual savings 
between $16 and $27 million (17,18); the Austrian analysis concludes that HTA recommendations had 
led to a “significant” reduction in expenditure, but deems precise monetary quantification impossible 
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(14,19). Another review, however, notes that while HTA’s effects on spending are unclear, the guidance 
of the United Kingdom’s NICE has led to an increase in spending, rather than decrease (10). The 
immediate and medium-term budgetary consequences of establishing an HTA body in low-resource 
contexts, have not been investigated by any study in Hailey and colleagues’ recent review (9). 
In short, the empirical benefits of HTA are at present unclear. We know little about how HTA affects 
patients’ health and access to care, and little about what it does to public budgets.  
 
Clear costs 
For a field with “assessment” in its name, the absence of empirical evaluation is surprising. Policy 
evaluation is a complex exercise, in this case further complicated by the lack of a uniform recipe for 
design and implementation of HTA processes (or, for that matter, consensus on HTA methodology) 
across countries. The real-world variation might explain why much of the HTA literature focuses on the 
“uptake” of HTA by decision-makers – the tacit assumption being that impact can only be measured 
under ideal conditions, where expertise reigns unhindered by politics. However, this is of little relevance 
to policy-makers looking for real-world success stories and lesson-drawing opportunities from other 
countries’ experience with HTA.  
The upfront costs, on the other hand, are relatively clear. Setting up an HTA body is not cheap: German 
IQWiG has an annual budget of approximately EUR 13 million (USD 14.8 million); Polish AOTMiT 
EUR 3.5 million; Belgian KCE EUR 10 million (20). To compare: KCE’s budget represents about 30% 
of the annual budget of a large university hospital in the Czech Republic (21). Further, there is a concern 
that HTA might in effect increase expenditure. An independent with decision-making powers HTA 
agency may prioritize evidence of cost-effectiveness or relative effectiveness over budget impact (more 
than the ministry of health or payers), leading to coverage of technologies that would have otherwise been 
denied reimbursement. Even a purely advisory body may make implicit rationing difficult for decision-
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makers, and bring unwanted attention to the lack of funds or inefficiencies in the health system. Likewise, 
introducing a new institution may destabilize the practice of delaying reimbursement decisions, common 
to some resource-tight countries. While all of these potentialities may ultimately be good news for 
patients, they are unlikely to be immediately attractive to policy-makers focused on health gains and cost-
containment in the short term.  
HTA is also not easy to implement: creating new institutions and adjusting pricing and reimbursement 
processes requires more than a couple of days’ worth of legislative effort. In addition, many low-resource 
countries first need to train sufficient numbers of HTA experts. Both the financial costs and the effort 
might well be worth it – if policy-makers can be convinced HTA delivers on its promises.  
 
Modernizing mission  
Beyond the uncertain effects of HTA on health systems, an additional promise of HTA concerns its 
consequences for decision-making styles and cultures and for social justice. Some evaluations suggest, in 
line with Weiss’ “Enlightenment” conceptualization of the knowledge-policy relationship (22), that HTA 
acts by changing mindsets rather than immediately determining actions (12,14). Institutionalized HTA 
marks a departure from the opaque and arbitrary pricing and reimbursement practices customary in many 
countries. It is a departure underpinned by normative and epistemic beliefs in the superiority of evidence-
based decisions, independence of expert input, transparency and inclusiveness of social actors 
(“stakeholder dialogue”) (23). These are linked to the rise of evidence-based medicine (24) and perhaps 
more generally “good governance” and the trend of expert decision-making (25). None of these principles 
guarantee improving the quality, equity or sustainability of health systems. Whether rational-
comprehensive policy-making leads to better outcomes than “muddling through” incremental 
adjustments, has been a debate for decades (26), and good governance probably attracts more critics than 
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advocates (27). However, for some decision-makers, a focus on evidence, transparency and inclusiveness 
may represent values in themselves – worth the budget of a provincial hospital. 
An equally compelling promise of HTA (and equally difficult to quantify) is connected to its potential of 
increasing procedural justice in allocative decisions (28). Here, too, much depends on the details of the 
institutional setup of HTA – Daniels and van der Wilt, for instance, argue that a deliberative element is 
necessary for HTA to produce legitimate and fair decisions (29). However, HTA’s proposal to reduce 
arbitrary decisions touches directly on health systems’ ambitions of equity and societies’ desires for fair 
institutions.  
For many low- and middle-income countries today, the combination of theoretical and normative 
arguments for HTA offers a powerful modernizing vision for their health systems. For example, a 2014 
World Health Assembly resolution mentions both efficiency concerns and principles of evidence-based 
policy-making as reasons for encouraging HTA, especially in low-income countries (30). This 
modernizing potential makes HTA hard to dismiss, despite a surprising absence of evidence of its effects 
after more than two decades of existence. Other policies, from international reference pricing to risk-
sharing agreements or implicit rationing, may be easier to implement and fare better at containing costs, 
but none offer as complex a promise as HTA. This makes HTA currently a policy without direct 
alternatives, potentially attractive to policy-makers around the world for many different reasons.  
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